Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: A Randomized Controlled Trial

Phase 3

• Conditions: Patients with mild to moderate plaque type psoriasis who willing to apply CanPatch; Cannabis; Psoriasis; Microbiota; Cannabidiol

• Registration Number: TCTR20220518004
• Lead Sponsor: Thai Traditional Medical Knowledge Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-18
• Last Update Posted: 19 August 2024
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. More than 18 years old
2. Has been diagnosed with mild to moderate plaque type psoriasis with baseline PASI score less than 10 by a board-certified dermatologist
3. Have two or more psoriasis plaque of comparable size and severity
4. Abstain from topical treatment for psoriasis more than 2 weeks prior to the research
5. Could completely contemplate Thai language
6. Have ability and willingness to sign inform-consent form for the research

Exclusion Criteria

1. Pregnant women or women who are currently breastfed.
2. Contraindication to cannabis transdermal patch (Allergy to products of CanPatch or have history of severe cardiovascular disease, liver disease, renal disease and serious psychiatric disease)
3. Addictive behavior or previously defined as abuse of cannabis (Determined through patient interview and medical records)
4. Receive biologics therapy for psoriasis treatments
5. Patients who have had less than 12 weeks of systemic conventional therapy for psoriasis (oral medications or phototherapy)
6. Patients who have been receiving systemic conventional therapy for psoriasis (oral medications or phototherapy) for more than 12 weeks, but who have seen variations in psoriasis symptoms or adjustments to their medication or phototherapy regimen within the past 12 weeks.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy 3 month Local Psoriasis Severity Index

Secondary Outcome Measures

Name	Time	Method
Efficacy 0,1,2,3 months Itch score by visual analog scale,Safety 1,2,3 months Adverse event reporting,Microbial alteration 0,3 months The alpha-diversity, beta-diversity and relative abundance of microbiota,Efficacy 0,1,2 months Local Psoriasis Severity Index